Locally Advanced Head and Neck Squamous Cell Carcinoma Clinical Trial
Official title:
Radiotherapy Plus Xevinapant or Placebo in Older Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma: a Randomized Phase II Study RAVINA
This is a multicenter, randomized, placebo-controlled, triple blind, phase II study to determine the efficacy and safety of xevinapant with radiotherapy in older patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC) of oral cavity, oropharynx, hypopharynx, or larynx. Upon confirmation of eligibility, subjects will be enrolled and randomized in a 1:1 ratio to: - Arm A: 3 cycles of xevinapant (200 mg/day from Day 1 to 14, per cycle) + intensive modulated radiotherapy (IMRT) followed by 3 cycles of xevinapant in monotherapy phase (200 mg/day from Day 1 to 14, per cycle) - Arm B: 3 cycles of placebo (from Day 1 to 14, per cycle) + IMRT followed by 3 cycles of placebo in monotherapy phase (from Day 1 to 14, per cycle). Patients will be stratified by institution, disease location/p16 status (p16 positive oropharyngeal cancer, versus others), G8 score. Three strata for the G8 will be used (>14, versus 11-14 versus <11). Patients will undergo imaging in week 20 and upon clinical suspicion of progression/recurrence. Clinical examination will take place every 12 weeks in the first 3 years.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03426657 -
Radiotherapy With Double Checkpoint Blockade of Locally Advanced HNSCC
|
Phase 2 | |
Recruiting |
NCT05172245 -
Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer
|
Phase 1 | |
Completed |
NCT04949503 -
A Real-world Study of the Efficacy and Safety of Nimotuzumab in Combination With Chemoradiotherapy for LASCCHN
|
||
Completed |
NCT04870840 -
Image-guided Proton Therapy for the Treatment of Locally Advanced Unresectable Head and Neck Cancer
|
Phase 1 | |
Completed |
NCT04541355 -
Sodium Thiosulfate in Preventing Ototoxicity for Squamous Cell Cancer Patients Undergoing Chemoradiation With Cisplatin
|
Phase 2 | |
Recruiting |
NCT03649048 -
Low-Dose Weekly vs High-Dose Cisplatin
|
N/A | |
Not yet recruiting |
NCT05773079 -
Toripalimab Maintenance for Locally Advanced Head and Neck Squamous Cell Carcinoma
|
Phase 2 | |
Not yet recruiting |
NCT05861557 -
Neoadjuvant Radiotherapy Combined With Toripalimab for Locally Advanced Head and Neck Squamous Cell Carcinoma
|
Phase 2 | |
Recruiting |
NCT05527782 -
Induction Modified TPF Followed by Concurrent Chemoradiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck
|
Phase 2 | |
Recruiting |
NCT05269381 -
Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT05376553 -
Study of Cemiplimab - TP Induction Chemotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck
|
Phase 1 | |
Withdrawn |
NCT03875053 -
Home Sleep Apnea Machine in Evaluating Obstructive Sleep Apnea in Patients With Stage III-IV Head and Neck Cancer
|
N/A | |
Recruiting |
NCT04892173 -
NBTXR3 With or Without Cetuximab in LA-HNSCC
|
Phase 3 | |
Withdrawn |
NCT05743270 -
Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN
|
Phase 2 | |
Recruiting |
NCT06240689 -
A Prospective Randomized Controlled Study of Immune Checkpoint Maintenance Therapy After Radiotherapy and Chemotherapy for Locally Advanced Head and Neck Tumors Based on Peripheral Blood CD8Tex Detection in Peripheral Blood
|
Phase 2 | |
Suspended |
NCT04454489 -
Quad Shot Radiotherapy in Combination With Immune Checkpoint Inhibition
|
Phase 2 | |
Completed |
NCT01689194 -
Efficacy Study of Genexol-PM and Cisplatin in Locally Advanced Head and Neck Cancer
|
Phase 2 | |
Recruiting |
NCT05245682 -
Tolinapant and Radiation for Cisplatin-Ineligible, Previously Untreated, Locally Advanced Head and Neck Cancer
|
Early Phase 1 | |
Recruiting |
NCT04947241 -
Toripalimab Combined With Gemcitabine and Cisplatin Treating Resectable Locally Advanced HNSCC
|
Phase 1 | |
Recruiting |
NCT06129864 -
A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
|
Phase 3 |